Authors

Latest:

Importance of Real-World Data in Supporting Treatment Options

Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.

Masatoshi Kudo, MD, PhD, Kindai University

Latest:

Future Directions of HCC

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).

Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine

Latest:

Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma

Massimo Cristofanilli, MD

Latest:

Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

Massimo Cristofanilli, MD, FACP

Latest:

Closing Remarks on Treating Patients with HR+ Breast Cancer

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

Massimo Di Maio, PhD

Latest:

Importance of Quality of Life Endpoints in Clinical Trials

Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.

Materials Provided by Children's Hospital Boston

Latest:

New Angiogenesis Inhibitor May Be Effective Against a Broad Range of Cancers

Researchers at Children's Hospital Boston say that they have developed the first oral, broad-spectrum angiogenesis inhibitor that may offer a potential nontoxic therapy for a wide range of cancers. The drug was formulated through nanotechnology and has shown promising anticancer results in mice.

Mateusz Opyrchal, MD, PhD

Latest:

Dr. Opyrchal on the Current State of Biomarkers in TNBC

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Mathew Hall, MD

Latest:

Dr. Mathew Hall on the Impact of PSA Screening Recommendations

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

Mathias J. Rummel, MD, PhD

Latest:

Dr. Rummel on the Chemical Structure of Bendamustine

Dr. Mathias Rummel, from the University Hospital Giessen in Germany, on the Bendamustine Chemical Structure

Mathieu d?Aquin, Jean Lieber

Latest:

Decision Support Systems in Oncology: Are we there yet?

The push for clinical decision support technology in medicine is a logical consequence of our experiences as consumers and the need for intelligent support at the bedside.

Matt Brow

Latest:

Understanding the Implications of Mandatory Vendor Imposition in Oncology

The rising costs of healthcare have caused payers to analyze spending and take measures to contain costs.

Matt Mahady

Latest:

Strong Evidence for Palliative Care Intervention But Adoption Is Slow

As more studies link aggressive end-of-life oncology care to problems such as suboptimal cost and quality outcomes, experts are increasingly proposing earlier, more comprehensive palliative care interventions.

Matteo Lambertini, MD, PhD, University of Genova IRCCS Ospedale Policlinico San Martino

Latest:

Timing Fertility Preservation in Patients With Breast Cancer Undergoing Surgery

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review fertility preservation strategies in the context of patients with breast cancer undergoing surgery.

Matthew A. Gubens, MD, MS

Latest:

Dr. Gubens Discusses the Role of PD-L1 in Patients With NSCLC

Matthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.

Matthew A. Lunning, DO

Latest:

Future Directions and Unmet Needs in Relapsed/Refractory MCL

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Matthew A. Powell, MD, Washington University in St. Louis

Latest:

Unmet Needs in the Management of Patients With Advanced Endometrial Cancer

Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.

Matthew Abramowitz, MD

Latest:

A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Matthew B. Yurgelun, MD

Latest:

Updates on Imaging-Based Pancreatic Cancer Surveillance for Individuals With Increased Genetic and Familial Risk

Recent years have brought tremendous progress in demonstrating that there is hope for improving mortality from pancreatic ductal adenocarcinoma through early detection.

Matthew Borst, MD

Latest:

Dr. Borst on Homologous Recombination Deficiency in Patients With Ovarian Cancer

Matthew Borst, MD, director, GYN/Oncology, Banner Good Samaritan Regional Medical Center, clinical assistant professor of medicine, University of Arizona, Arizona Oncology, discusses homologous recombination deficiency (HRD) in patients with ovarian cancer.